🥂 Happy New Year 2026: Cure51’s Progress in Cancer Research and the Rosalind Study

Reflecting on Cure51’s Cancer Research Achievements in 2025

As we begin 2026, we wanted to pause for a moment to look back on the year we’ve just lived together, to say thank you and share some major updates in Cancer research and global oncology partnerships.

2025 was a year of strong and meaningful acceleration for Cure51: a year of breakthrough progress in Cancer research, with scientific acceleration across Cure51’s mission to understand and harness exceptional Cancer survivor biology.

We made progress on many fronts at once, and we did so collectively. Our team continued to grow and today brings together 59 collaborators, each contributing their expertise, energy and commitment to a shared mission.

Our network also expanded at an unprecedented pace. We now work with 112 partner centers across 63 countries, including 75 new centers and 27 new countries that joined us in 2025 alone, strengthening our worldwide collaboration on Cancer research and translational science.
This global reach allows us to learn from exceptional clinical trajectories, to embrace diversity and to build a truly international effort in Cancer research.

Advancing the Rosalind Study: Global Research on Exceptional Cancer Survivors

On the scientific side, our Rosalind Study reached an important milestone. Our biobanking efforts accelerated, with 1064 patients’ samples collected to date in our central lab at Gustave Roussy Cancer Campus. Behind each number is a patient, a clinical team and an act of trust, and we never lose sight of that responsibility.

As we move into 2026, our ambition is clear: to validate what we have built through the development of novel therapeutic programs.
We are now testing our first therapeutic targets in vitro, strengthening our discovery capabilities to better understand survivor biology, and advancing toward our first pharmaceutical partnerships to deliver clinical benefit to patients as quickly as possible. These are decisive milestones for us, reflecting the rigor, patience and collective effort that define our culture.
But beyond milestones and metrics, 2026 is also about people. The patients, scientists, clinicians, partners and future teammates who share the same determination to transform Cancer care. We are deeply motivated to continue this journey with you, and to welcome new talents who want to build, question and move forward with us.

Thank you for your trust, your engagement and your support.

We wish you and your loved ones a healthy, meaningful and hopeful year ahead.

Updated: Jan 2, 2026